Quidel Stock News

Investing in key healthcare stocks can offset some of the investor risk related to the omicron variant.

This article was originally published on TipRanks.com Quidel Corporation (NASDAQ: QDEL), one of the largest American manufacturers of diagnostic healthcare products, has agreed to snap up Nasdaq listed The post Quidel to Acquire Ortho for $6B; Shares Slide 17% appeared first on Smarter Analyst .

Quidel's (QDEL) latest buyout is expected to expand its point-of-care diagnostics portfolio as well as geographic footprint.

The virology specimen collection market is divided into blood, nasopharyngeal, nasal, throat, cervical, oral and different examples. The blood fragment represented the most elevated development rate. Factors, for example, the rising number of blood gifts and rising commonness of viral

Quidel Corp. (QDEL) shares closed today 17.4% lower than it did at the end of yesterday. The stock is currently down 7.5% year-to-date, down 18.3% over the past 12 months, and up 719.3% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $180.06 and as low as $147.44 this week.Shares closed 48.2% below its 52-week high and 33.0% above its 52-week low.Trading volume this week was 39.8% lower than the 10-day average and 10.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at -0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -136.7% The company's stock price performance over the past 12 months lags the peer average by -203.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 7.1% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NEW YORK , Dec. 23, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Ortho Clinical Diagnostics Holdings plc ("Ortho" or the "Company") (NASDAQ: OCDX ), in connection with the proposed acquisition of the Company by Quidel Corporation ("Quidel") (NASDAQ: QDEL ). Under the terms of the merger agreement, the Company''s shareholders will receive $7.14 in cash and 0.1055 shares of common stock in the combined company for each Ortho common share they own, representing implied per-share merger consideration of approximately $24.68 based upon Quidel''s December 22, 2021 closing price of $166.24 . Upon completion of the transaction, Ortho shareholders are expected to own approximately 38% of the combined company. The transaction is valued at approximately $6.0 billion . Full story available on Benzinga.com

Stocks that traded heavily or had substantial price changes Thursday: Scientific Games Corp., up $5.57 to $67.75. The company withdrew its offer to buy the remaining 19% of

Stocks that traded heavily or had substantial price changes Thursday: Scientific Games Corp., up $5.57 to $67.75. The company withdrew

Quidel Corporation (NASDAQ:QDEL) at last check was buoying at $136.54 on Thursday, December 23 with a fall of -17.87% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $166.24 and 5Y monthly beta was reading -0.07 with its price kept floating in Quidel Corporation (QDEL) At $136.54: Is It Worth Your Interest? Read More »

NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by Quidel Corporation (NASDAQ: QDEL).

Related Stocks: ARGX , MGNX , CUTR , RNA , FULC , ITOS , TMO , PEN , TNYA , SGHT , AADI , RCOR , PTGX , MDXG , CSTL , AGEN , ABUS , QDEL , TRIL , CHAQ , BCTG , ITMR , RACA ,

Quidel will acquire OCDX stock for $24.68 per share and newly issued stock. The transaction will be worth a total of $6 billion.